Lunai Bioworks shares surge 33.35% intraday after acquiring CNS drug assets from Clemann Group.

Lunai Bioworks surged 33.35% in intraday trading, following the company's announcement of a $20 million strategic acquisition of Clemann Group's blood-brain barrier delivery technology and CNS Alzheimer's drug assets, aimed at overcoming critical bottlenecks in CNS drug development. The clinical-stage biotech firm, which operates through the RENB, BioSymetrics, and RENC divisions focusing on AI-driven drug discovery and precision medicine, executed the deal with a fixed conversion price of $1.50 per share.